Exhibit 10.1 


 


WARRANT
EXERCISE AGREEMENT


 


This Warrant Exercise Agreement (this “Agreement”),
dated as of October 7, 2020, is by and between Applied DNA Sciences, Inc., a Delaware corporation (the “Company”),
and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock,
par value $0.001 per share (the “Common Stock”).


 


WHEREAS, the Holder beneficially owns in the
aggregate the number of warrants to purchase Common Stock issued pursuant to the warrant agreement dated as of November 15,
2019, by and between the Company and American Stock Transfer & Trust Company, LLC, a New York limited liability trust
company, as warrant agent (the “Original Warrant Agreement”), with an exercise price of $5.25 per share that
are exercisable until November 15, 2024, as set forth on the Holder’s signature page hereto (the “Original
Warrants”).


 


WHEREAS, simultaneous with the execution hereof,
the Holder is exercising certain of such Original Warrants (the “First Exercised Warrants”) in the amounts set
forth on the Holder’s signature page hereto.


 


WHEREAS, the Company desires to repay in full
all principal and accrued interest under that certain Secured Convertible Note, dated July 16, 2019, issued by the Company
in favor of the Holder or its affiliates (as amended, restated, supplemented or otherwise modified from time to time and in effect
on the date hereof, the “Note”).


 


WHEREAS, in consideration of the Holder’s
exercise of the First Exercised Warrants and the consent by the holder of the Note to the repayment of the Note, the Company shall
issue to the Holder, in addition to the shares of Common Stock to which such exercising Holder is entitled pursuant to the exercise
of such First Exercised Warrants, new warrants (the “New Warrants”) for the number of shares of Common Stock
equal to fifty percent (50%) of the number of shares of Common Stock issued pursuant to the exercise of the First Exercised Warrants.


 


WHEREAS, the Company has agreed that in the
event the Holder exercises any additional Original Warrants (other than the First Exercised Warrants) (the “Second Exercised
Warrants”) within 90 days from the date hereof (such 90 day period, the “90 Day Exercise Period”),
the Company shall issue to the Holder, in addition to the shares of Common Stock to which such exercising Holder is entitled pursuant
to the exercise of such Second Exercised Warrants, New Warrants for the number of shares of Common Stock equal to fifty percent
(50%) of the number of shares of Common Stock issued pursuant to the exercise of the Second Exercised Warrants.


 


WHEREAS, the shares of Common Stock underlying
the Original Warrants are referred to herein as the “Warrant Shares”. The shares of Common Stock underlying
the New Warrants are referred to herein as the “New Warrant Shares” and collectively with the New Warrants,
the “Securities”.


 


WHEREAS, simultaneous with the execution hereof,
the Holder is entering into a Registration Rights Agreement with the Company for the New Warrant Shares.


 






     


     


    

 


NOW, THEREFORE, IN CONSIDERATION of the
mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy of which are hereby
acknowledged, the Holder and the Company agree as follows:


 


ARTICLE I

DEFINITIONS


 


Section 1.1.           Definitions.
Capitalized terms not defined in this Agreement shall have the meanings ascribed to such terms in the Original Warrant Agreement.


 


ARTICLE II

EXERCISE OF ORIGINAL WARRANTS


 


Section 2.1.           Exercise
of Warrants.


 


(a)            Contemporaneous
with the execution of this Agreement, the Holder shall exercise the First Exercised Warrants pursuant to the terms of the Original
Warrant Agreement and the Company shall issue to the Holder, in addition to the shares of Common Stock to which such exercising
Holder is entitled pursuant to the exercise of such First Exercised Warrants, New Warrants for the number of shares of Common Stock
equal to fifty percent (50%) of the number of shares of Common Stock issued pursuant to the exercise of the First Exercised Warrants.
The Holder shall deliver the Notice of Exercise (as defined in the Original Warrant Agreement) and the aggregate cash exercise
price for such First Exercised Warrants and the Company shall deliver the related Warrant Shares pursuant to the terms of the Original
Warrant Agreement and shall deliver the related New Warrants within two Trading Days of the receipt by the Company of the payment
by the Holder of the exercise price. Each New Warrant issued pursuant to this Section 2.1(a) will have an exercise price
for the purchase of one share of Common Stock equal to the closing price of the Company’s Common Stock as reported by Nasdaq
for the date the related Notice of Exercise is received by the Company and will be in the form attached hereto as Exhibit A
(the “New Warrant Form”). The date of the closing of the exercise of the First Exercised Warrants shall be referred
to herein as a “Closing Date.”


 


(b)            Subject
to the conditions of the Original Warrant Agreement, the Company and the Holder hereby agree that in the event the Holder exercises
additional Original Warrants (other than the First Exercised Warrants) (the “Second Exercised Warrants”) on
one or more days during the 90 Day Exercise Period, the Company shall issue to the Holder, in addition to the shares of Common
Stock to which such exercising Holder is entitled pursuant to the exercise of such Second Exercised Warrants, New Warrants for
the number of shares of Common Stock equal to fifty percent (50%) of the number of shares of Common Stock issued pursuant to the
exercise of such Second Exercised Warrants. The Holder shall deliver each Notice of Exercise (as defined in the Original Warrant
Agreement) and the aggregate cash exercise price for such Second Exercised Warrants specified in such Notice of Exercise and the
Company shall deliver the related Warrant Shares pursuant to the terms of the Original Warrant Agreement and shall deliver the
related New Warrants within two Trading Days of the receipt by the Company of the payment by the Holder of the exercise price.
Each New Warrant issued pursuant to this Section 2.1(b) will have an exercise price for the purchase of one share of
Common Stock equal to the closing price of the Company’s Common Stock as reported by Nasdaq for the date the related Notice
of Exercise is received by the Company and will be in the form of the New Warrant Form. Each date of the closing of the exercise
of the Second Exercised Warrants shall be referred to herein as a “Closing Date.”


 






     


     


    

 


(c)            The
Company acknowledges and agrees that the obligations of the Holder under this Agreement is several and not joint with the obligations
of any other holder of warrants originally issued together with the Original Warrants (each, an “Other Holder”)
under any other agreement related to the exercise of such warrants (“Other Warrant Exercise Agreement”), and
the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other
Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall
be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated by this Agreement. The Holder confirms that it has independently participated
in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be
entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement,
and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.


 


Section 2.3.           Legends;
Restricted Securities.


 


(a)            The
Holder understands that the New Warrants and the shares of Common Stock underlying the New Warrants are not, and may never be,
registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any
state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially similar to the
following:


 


“THIS SECURITY HAS NOT BEEN
REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT
BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER
THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.”


 






     


     


    

 


(b)            Certificates
evidencing shares of Common Stock underlying the New Warrants shall not contain any legend (including the legend set forth in Section 2.3(a) hereof),
(i) while a registration statement covering the resale of such Common Stock is effective under the Securities Act, (ii) following
any sale of such Common Stock pursuant to Rule 144, (iii) if such Common Stock is eligible for sale under Rule 144,
without the requirement for the Company to be in compliance with the current public information required under Rule 144 as
to such Common Stock and without volume or manner-of-sale restrictions, (iv) if such Common Stock may be sold under Rule 144
and the Company is then in compliance with the current public information required under Rule 144 as to such Common Stock,
or (v) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Securities and Exchange Commission (the “Commission”)). The Company
shall cause its counsel to issue a legal opinion to the transfer agent promptly after the Delegend Date (as defined below) if required
by the Company and/or the transfer agent to effect the removal of the legend hereunder, which opinion shall be in form and substance
reasonably acceptable to the Holder. If such Common Stock may be sold under Rule 144 without the requirement for the Company
to be in compliance with the current public information required under Rule 144 or if such legend is not otherwise required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Commission) then such Common Stock shall be issued free of all legends. The Company agrees that following the Delegend Date
or at such time as such legend is no longer required under this Section 2.3(b), it will, no later than two (2) Trading
Days following the delivery by the Holder to the Company or the transfer agent of a certificate representing the Common Stock underlying
the New Warrants issued with a restrictive legend (such second Trading Day, the “Legend Removal Date”), deliver
or cause to be delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends
or, at the request of the Holder shall credit the account of the Holder’s prime broker with the Depository Trust Company
System as directed by the Holder. The Company may not make any notation on its records or give instructions to the transfer agent
that enlarge the restrictions on transfer set forth in this Section 2.3(b). “Delegend Date” means the earliest
of the date that (a) a registration statement with respect to the Common Stock has been declared effective by the Commission
or (b) all of the Common Stock has been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the
requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume
or manner-of-sale restrictions or (c) following the six (6) month anniversary of (I) the applicable Closing Date
if a New Warrant is exercised pursuant to a cashless exercise or (II) the date of the related cash exercise of the New Warrants
provided, in each case that the applicable holder of the New Warrants or the Common Stock, as the case may be, is not an affiliate
of the Company, the Company is in compliance with the current public information required under Rule 144 (“Current
Public Information Requirement”) and all such Common Stock may be sold pursuant to Rule 144 or an exemption from
registration under Section 4(a)(1) of the Securities Act without volume or manner-of-sale restrictions; provided, further,
however, that if the Company fails to comply with the Current Public Information Requirement at any time following the applicable
six (6) month anniversary set forth above and the one (1) year anniversary of the applicable Closing Date, the Company
shall promptly provide notice to the Holder and the Holder undertakes not to sell such Common Stock pursuant to Rule 144 until
the Company notifies the Holder that it has regained compliance with the Current Public Information Requirement; and provided
further, that if a delegending is in effect solely as the result of the effectiveness of a registration statement covering
the resale of any Common Stock, the Holder undertakes not to sell any such Common Stock if the Holder is notified or otherwise
becomes aware that such registration statement has been withdrawn or suspended, contains a material misstatement or omission or
has become stale. The Holder agrees with the Company that the Holder will sell or transfer any New Warrants or shares of Common
Stock underlying New Warrants pursuant to either the registration requirements of the Securities Act, including any applicable
prospectus delivery requirements, or an exemption therefrom, and that if such securities are sold pursuant to a registration statement,
they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive
legend from certificates representing any such securities as set forth in this Section 2.3 or otherwise is predicated upon
the Company’s reliance upon this understanding.


 






     


     


    

 


Section 2.4.           Filing
of Form 8-K and Amendment to Registration Statement


 


. The Company shall issue a Current Report on Form 8-K,
reasonably acceptable to the Holder disclosing the material terms of the transactions contemplated hereby, which shall include
this form of Agreement (the “8-K Filing”) by 5:30 pm on the date hereof. From and after the issuance of the
8-K Filing, the Company represents to the Holder that it shall not be in possession of any material, nonpublic information received
from the Company or any of its officers, directors, employees or agents, that is not disclosed in the 8-K Filing. The Company shall
not and shall cause each of its officers, directors, employees and agents, not to, provide the Holder with any material, nonpublic
information regarding the Company from and after the date hereof without the express prior written consent of the Holder. To the
extent that the Company or any of its officers, directors, employees or agents, delivers any material, non-public information to
the Holder without the Holder’s consent, the Company hereby covenants and agrees that the Holder shall not have any duty
of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public information.


 


Section 2.5.           Reserved.


 


ARTICLE III

REPRESENTATIONS AND WARRANTIES


 


Section 3.1.           Representations
and Warranties of the Company. The Company hereby makes the representations and warranties set forth below to the Holder that
as of the date of its execution of this Agreement:


 


(a)            Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement
by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action
on the part of such Company and no further action is required by such Company, its board of directors or its stockholders in connection
therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.


 






     


     


    

 


(b)            Organization.
The Company is a duly organized and validly existing corporation in good standing under the laws of the State of Delaware.


 


(c)            Registration
Statement. The Warrant Shares are registered for issuance on a Form S-1 Registration Statement and the Company knows of
no reasons why such registration statement shall not remain available for the issuance and resale of such Warrant Shares for the
foreseeable future. The Company shall use commercially reasonable efforts to keep the Registration Statement effective and available
for use by the Holder until all Warrant Shares underlying the Original Warrants are sold by the Holder.


 


(c)            No
Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of
the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s
certificate of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a
default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien
upon any of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument
(evidencing Company debt or otherwise) or other material understanding to which the Company is a party or by which any property
or asset of the Company is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.


 


(d)            Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Holder or its agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the
Holder will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Holder regarding the Company and its Subsidiaries, their respective businesses
and the transactions contemplated hereby, including but not limited to the disclosure set forth in the SEC Reports, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make
the statements made therein, in light of the circumstances under which they were made, not misleading. As used herein, “SEC
Reports” means all reports, schedules, forms, statements and other documents required to be filed by the Company with
the Commission pursuant to the reporting requirements of the Securities and Exchange Act of 1934, as amended (the “Exchange
Act”), including all exhibits included therein and financial statements, notes and schedules thereto and documents incorporated
by reference therein.


 






     


     


    

 


(f)             Issuance
of Securities. The issuance of the New Warrants is duly authorized and, upon issuance in accordance with the terms of this
Agreement, the New Warrants shall be validly issued and free from all preemptive or similar rights (except for those which have
been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances with respect to the issue thereof.
As of each Closing Date, a number of shares of Common Stock shall have been duly authorized and reserved for issuance which equals
or exceeds the maximum number of Warrant Shares issuable upon exercise of the applicable New Warrants (without taking into account
any limitations on the exercise of the New Warrants set forth therein). Upon exercise of the New Warrants in accordance with the
New Warrants, the New Warrant Shares when issued will be validly issued, fully paid and nonassessable and free from all preemptive
or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders being entitled
to all rights accorded to a holder of Common Stock. Assuming the accuracy of each of the representations and warranties set forth
in Section 3.2 of this Agreement, the offer and issuance by the Company of the New Warrants is exempt from registration under
the 1933Act.


 


(e)            No
General Solicitation. Neither the Company, nor any of its subsidiaries or affiliates, nor any person acting on its or their
behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection
with the offer or sale of the New Warrants.


 


(f)             No
Integrated Offering. None of the Company, its subsidiaries or any of their affiliates, nor any person acting on their behalf
has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration with prior
offerings or otherwise, or cause this offering of the Securities to require approval of shareholders of the Company for purposes
of the 1933 Act or any applicable shareholder approval provisions, including, without limitation, under the rules and regulations
of any exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation.
None of the Company, its subsidiaries, their affiliates nor any person acting on their behalf will take any action or steps that
would require registration of the issuance of any of the Securities under the 1933 Act or cause the offering of any of the Securities
to be integrated with other offerings for purposes of any such applicable shareholder approval provisions.


 


Section 3.2.           Representations
and Warranties of the Holder. The Holder hereby makes the representations and warranties set forth below to the Company that
as of the date of its execution of this Agreement.


 


(a)            Due
Authorization. The Holder represents and warrants that (i) the execution and delivery of this Agreement by it and the
consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on its behalf and
(ii) this Agreement has been duly executed and delivered by the Holder and constitutes the valid and binding obligation of
the Holder, enforceable against it in accordance with its terms.


 


(b)            No
Conflicts. The Holder represents and warrants that the execution, delivery and performance of this Agreement by the Holder
and the consummation by the Holder of the transactions contemplated hereby do not and will not: (i) conflict with or violate
any provision of the Holder’s organizational or charter documents, or (ii) conflict with or result in a violation of
any agreement, law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
which would interfere with the ability of the Holder to perform its obligations under this Agreement.


 






     


     


    

 


(c)            Access
to Information. The Holder acknowledges that it has had the opportunity to review this Agreement and the SEC Reports and has
been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives
of the Company concerning the terms and conditions of the exercise of the Original Warrants and the merits and risks of investing
in the Warrant Shares; (ii) access to information about the Company and its financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain
such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. The Holder acknowledges and agrees that neither Maxim Group,
LLC (the “Advisor “) nor any affiliate of the Advisor has provided the Holder with any information or advice
with respect to the Securities nor is such information or advice necessary or desired. Neither the Advisor nor any affiliate has
made or makes any representation as to the Company or the quality of the securities issued and issuable hereunder and the Advisor
and any affiliate may have acquired non-public information with respect to the Company which the Holder agrees need not be provided
to it. In connection with the issuance of the securities hereunder to the Holder, neither the Advisor nor any of its affiliates
has acted as a financial advisor or fiduciary to the Holder.


 


(d)            Holder
Status. The Holder represents and warrants that is an “accredited investor” as defined in Rule 501 under the
Securities Act.


 


(e)            Knowledge.
The Holder, either alone or together with its representatives, has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has
so evaluated the merits and risks of such investment. The Holder is able to bear the economic risk of an investment in the Securities
and, at the present time, is able to afford a complete loss of such investment.


 


ARTICLE IV


 


Section 4.1.           Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be made by email
to the email address of the Holder set forth on Holders’ signature page.


 


Section 4.2.           Survival.
All warranties and representations (as of the date such warranties and representations were made) made herein or in any certificate
or other instrument delivered by it or on its behalf under this Agreement shall be considered to have been relied upon by the
parties hereto and shall survive the issuance of the New Warrants. This Agreement shall inure to the benefit of and be binding
upon the successors and permitted assigns of each of the parties; provided however that no party may assign this Agreement or
the obligations and rights of such party hereunder without the prior written consent of the other parties hereto.


 






     


     


    




 


Section 4.3.           Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.


 


Section 4.4.           Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.


 


Section 4.5.           Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
pursuant to the Governing Law provision of the Original Warrant Agreement.


 


Section 4.6.           Entire
Agreement. The Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.


 


Section 4.7.           Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


Section 4.8.           Fees
and Expenses. Except as expressly set forth herein, each party shall pay the fees and expenses of its advisers, counsel, accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties
levied in connection with the delivery of any Warrant Shares.


 


(remainder of page intentionally
left blank; signature page follows)


 






     


     


    

 








IN WITNESS WHEREOF , the undersigned
have executed this Warrant Exercise Agreement as of the date first written above.


 


COMPANY:


 


Applied DNA Sciences, Inc.


 


	By:	/s/ Beth Jantzen	 
	Name:	Beth Jantzen	 
	Title:	CFO	 









 






     


     


    

 


[HOLDER
SIGNATURE PAGES TO

WARRANT EXERCISE AGREEMENT]


 


IN WITNESS WHEREOF, the undersigned have caused
this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.


 


	Name of Holder:	 	Dillon Hill Capital LLC


 


	Signature of Authorized Signatory of Holder:	 	/s/ Bruce Grossman


 


	Name of Authorized Signatory:	 	Bruce Grossman


 


	Title of Authorized Signatory:	 	CEO


 


	Email Address of Holder:	 	[Intentionally omitted.]


 


Details for Exercised Warrants


 


	Number of Original Warrants held:	 	 


 


	Number of First Exercised Warrants to be exercised:	 	200,000


 


	Aggregate Exercise Price of First Exercised Warrants to be exercised:	 	$1,050,000


 


	Warrant Shares underlying First Exercised Warrants to be exercised:	 	200,000


 


	Number of New Warrants to be issued upon exercise of the First Exercised Warrants:	 	100,000